Cargando…

A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction

OBJECTIVE: To systematically review the efficacy and safety of sacubitril and valsartan in treating acute myocardial infarction complicated with heart failure and to observe whether it can further improve patients’ cardiac function, delay left ventricular remodeling, and reduce major adverse cardiov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiaomin, Zhu, Hongjun, Zheng, Yawei, Tan, Xiaodong, Tong, Xinyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592716/ https://www.ncbi.nlm.nih.gov/pubmed/36304540 http://dx.doi.org/10.3389/fcvm.2022.953948

Ejemplares similares

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
por: Yang, Pei, et al.
Publicado: (2023)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
por: Yang, Pei, et al.
Publicado: (2022)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Transfer RNA-derived small RNAs and their potential roles in the therapeutic heterogeneity of sacubitril/valsartan in heart failure patients after acute myocardial infarction
por: Su, Jia, et al.
Publicado: (2022)

Sacubitril/valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function
por: Hajra, Adrija, et al.
Publicado: (2019)

Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
por: Litwin, Sheldon E., et al.
Publicado: (2022)

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
por: Burgdorf, Christof, et al.
Publicado: (2021)

Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan
por: Hsu, Chien-Yi, et al.
Publicado: (2022)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
por: Jiang, Juan, et al.
Publicado: (2023)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Pascual-Figal, Domingo, et al.
Publicado: (2021)

Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Yu, Wanqian, et al.
Publicado: (2022)

Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later
por: Tao, Wenqi, et al.
Publicado: (2023)

Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol
por: Lee, Vivian, et al.
Publicado: (2023)

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
por: Pathadka, Swathi, et al.
Publicado: (2021)

Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea
por: Pelaia, Corrado, et al.
Publicado: (2022)

Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials
por: Song, Yinyin, et al.
Publicado: (2022)

Clinical efficacy of sacubitril-valsartan combined with acute ST-segment elevation myocardial infarction after reperfusion: A systematic review and meta-analysis
por: Zhang, Dong, et al.
Publicado: (2022)

Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis
por: Monosilio, Sara, et al.
Publicado: (2022)

Sacubitril/Valsartan: Potential Impact of ARNi “Beyond the Wall” of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19
por: Rubattu, Speranza, et al.
Publicado: (2020)

Impact of Sacubitril/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: Hemodynamic or pleiotropism?
por: Mapelli, Massimo, et al.
Publicado: (2022)

Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
por: Guo, Yanhong, et al.
Publicado: (2022)

The history and mystery of sacubitril/valsartan: From clinical trial to the real world
por: Zhang, Mingsong, et al.
Publicado: (2023)

Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials
por: Liu, Xue-Hui, et al.
Publicado: (2022)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation
por: Chen, Qingsong, et al.
Publicado: (2022)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
por: Fu, Sha, et al.
Publicado: (2021)

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology
por: Canale, Maria Laura, et al.
Publicado: (2022)

Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach
por: Zhou, Yu, et al.
Publicado: (2022)

Clinical observation of sacubitril valsartan sodium in the treatment of resistant hypertension: A randomized clinical trial
por: Lyu, Tian-Jiao, et al.
Publicado: (2022)

Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone
por: Sacharczuk, Wioletta, et al.
Publicado: (2023)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan
por: Correale, Michele, et al.
Publicado: (2023)

Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
por: Fabiani, Iacopo, et al.
Publicado: (2023)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
por: Bocchi, Edimar Alcides, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nkl7c6ri1oga0pbfne4850lofl